Journal Information
Vol. 60. Issue S2.
Lung cancer: New perspectives
Pages S13-S21 (October 2024)
Share
Share
Download PDF
More article options
Vol. 60. Issue S2.
Lung cancer: New perspectives
Pages S13-S21 (October 2024)
Original Article
Sex-specific Difference for Small Cell Lung Cancer from Immunotherapy Advancement
Diferencia sex-específica para el cáncer de pulmón de células pequeñas del avance de la inmunoterapia
Visits
1482
You Moa,b, Yiwei Qinc, Jian Shangguanb, Duncan Weia, Meng Wub, Dawei Chenb,1,
Corresponding author
dave0505@yeah.net

Corresponding author.
, Jinming Yua,b,1,
Corresponding author
sdyujinming@163.com

Corresponding author.
a Laboratory of Molecular Cardiology, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
b Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China
c Cheeloo College of Medicine, Shandong University
Highlights

  • Provided the first evidence of a significant difference in immunotherapy advance among sex for SCLC based population mortality. Patient with SCLC in women benefit significantly.

This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (7)
Show moreShow less
Additional material (1)
Special issue
This article is part of special issue:
Vol. 60. Issue S2

Lung cancer: New perspectives

More info
Abstract
Background

The treatment of lung cancer has witnessed significant progress, leading to improved survival rates among patients. It is important to assess the individual contributions of non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) to overall lung-cancer incidence and mortality trends based population, especially sex difference.

Methods

We analyzed lung cancer mortality based on subtype, gender, and calendar year. The Joinpoint software was used to identify any changes in incidence and trends in mortality.

Results

Incidence and incidence-based mortality declined from 2001 to 2019 both NSCLC and SCLC annually. The most significant decrease occurred between 2016 and 2019 with annual percent change of 5.71%. From 2012 to 2016, the incidence-based mortality of SCLC in women changed by 2.7% in tandem with incidence decreased 2.84%. Remarkably, the incidence-based mortality for women declined notably by 5.23% between 2016 and 2019, even as the incidence showed a less extent of decreasing (-2.59%). The survival rate for women was 15.2% in 2001, 19.3% in 2016, it had increased to 21.3% in 2018 but similar trends not in men. The survival curve showed the change in survival outcomes over time among men and women (median overall survival: 13 vs 23months) receiving immunotherapy for SCLC.

Conclusion

Population-level mortality from NSCLC and SCLC in the United States fell sharply from 2016 to 2019 as incidence deceased, and survival improved substantially. Our analysis suggests that approval for and use of immunotherapy may explain the mortality reduction observed during this period, with significant benefits especially for SCLC patient in women.

Keywords:
Sex differences
Lung cancer
Incidence
Mortality
Immunotherapy
Abbreviations:
NSCLC
SCLC
NCCN
EGFR
ALK
PD-1
PD-L1
SEER
ICD-O-3
APC
OS
Resumen
Antecedentes

El tratamiento del cáncer de pulmón ha experimentado un progreso significativo, lo que ha mejorado las tasas de supervivencia entre los pacientes. Es importante evaluar las contribuciones individuales del cáncer de pulmón de células no pequeñas (NSCLC) y el cáncer de pulmón de células pequeñas (SCLC) a la incidencia general de cáncer de pulmón y las tendencias de mortalidad basadas en la población, especialmente la diferencia de sexo.

Métodos

Se analizó la mortalidad por cáncer de pulmón en función del subtipo, el sexo y el año calendario. Se utilizó el software Joinpoint para identificar cualquier cambio en la incidencia y las tendencias en la mortalidad.

Resultados

La incidencia y la mortalidad basada en la incidencia disminuyeron anualmente de 2001 a 2019, tanto el CPNM como el CPCP. La disminución más significativa se produjo entre 2016 y 2019 con un cambio porcentual anual de 5.71%. De 2012 a 2016, la mortalidad basada en la incidencia de CPCP en mujeres cambió en un 2,7% en conjunto con la incidencia disminuyó en un 2,84%. Sorprendentemente, la mortalidad basada en la incidencia para las mujeres disminuyó notablemente en un 5,23% entre 2016 y 2019, incluso cuando la incidencia mostró una menor disminución (-2,59%). La tasa de supervivencia para las mujeres fue del 15,2% en 2001, del 19,3% en 2016, había aumentado al 21,3% en 2018, pero no hubo tendencias similares en los hombres. La curva de supervivencia mostró el cambio en los resultados de supervivencia a lo largo del tiempo entre hombres y mujeres (mediana de supervivencia global: 13 vs. 23 meses) que recibieron inmunoterapia para el CPCP.

Conclusión

La mortalidad a nivel de población por CPNM y CPCP en los Estados Unidos disminuyó drásticamente de 2016 a 2019 a medida que la incidencia falleció y la supervivencia mejoró sustancialmente. Nuestro análisis sugiere que la aprobación y el uso de la inmunoterapia pueden explicar la reducción de la mortalidad observada durante este período, con beneficios significativos especialmente para los pacientes con CPCP en mujeres.

Palabras clave:
Diferencias sexuales
Cáncer de pulmón
Incidencia
Mortalidad
Inmunoterapia

Article

These are the options to access the full texts of the publication Archivos de Bronconeumología
Member
If you are a member of SEPAR:
  • Go to >>>SEPAR<<< website and sign in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Archivos de Bronconeumología

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?